Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in temozolomide-primed MMR-proficient metastatic colorectal cancer
2018-001441-14Phase 2Active
- Sponsor
- IFOM
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and temozolomide in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by IFOM. Primary endpoint: Objective response rate. Started Jan 2021; status: active.
02
Drugs
pembrolizumabtemozolomide
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-001441-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001441-14.